NEW YORK, May 27, 2021 /PRNewswire/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) ("MindMed" or
the "Company") is pleased to announce that each of the resolutions
put before the annual and special meeting of shareholders held
today (the "Meeting") was passed by the requisite majority of
shareholders.
As described in the Company's management information circular
dated April 19, 2021 (the
"Circular"), Jamon Alexander Rahn,
Miriam Halperin Wernli, Stephen Hurst, Perry
Dellelce, Bruce Linton and
Brigid Makes were re-elected as directors of the Company. In
addition, as announced in the Company's press release dated
May 14, 2021, management of the
Company put forward Dr. Sarah Vinson
as an additional nominee for its board of directors. At the
Meeting, shareholders approved fixing the number of directors to be
elected at seven and approved all seven director nominees.
Furthermore, shareholders approved all other resolutions put
before the Meeting as described in the Circular, including: (i) the
appointment of RSM Canada LLP as auditor; (ii) the authorization to
amend and restate the articles of the Company; and (iii) the
reservation of an aggregate of 15% of the Company's issued and
outstanding subordinate voting shares under the Company's share
option plan and its performance share unit and restricted share
unit compensation plan. A total of 160,909,054 shares of the
Company (representing 39.52% of the combined total of votes
attaching to the issued and outstanding multiple voting shares and
subordinate voting shares) were voted in connection with the
Meeting. Each multiple voting share is entitled to 100 votes per
share.
MindMed CEO & Co-Founder J.R. Rahn noted, "We are
pleased with the active participation of our shareholders in
supporting our board members and our broader business plan. We aim
to ensure continued support through growing our dialogue with
existing and prospective shareholders."
The Company's investor presentation (the "Presentation") is also
available on the Company's website.
About MindMed
MindMed is a clinical-stage psychedelic
medicine biotech company that discovers, develops and deploys
psychedelic inspired medicines and therapies to address addiction
and mental illness. The Company is assembling a compelling drug
development pipeline of innovative treatments based on psychedelic
substances including Psilocybin, LSD, MDMA, DMT and an ibogaine
derivative, 18-MC. The MindMed executive team brings extensive
biopharmaceutical experience to MindMed's approach to developing
the next generation of psychedelic inspired medicines and
therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO exchange under the symbol MMED. MindMed is also traded
in Germany under the symbol
MMQ.
Forward-Looking Statements
Certain statements in this news release and the Presentation
related to the Company constitute "forward-looking information"
within the meaning of applicable securities laws and are
prospective in nature. Forward-looking information is not based on
historical facts, but rather on current expectations and
projections about future events and are therefore subject to risks
and uncertainties which could cause actual results to differ
materially from the future results expressed or implied by the
forward-looking statements. These statements generally can be
identified by the use of forward-looking words such as "will",
"may", "should", "could", "intend", "estimate", "plan",
"anticipate", "expect", "believe", "potential" or "continue", or
the negative thereof or similar variations. Forward-looking
information in this news release and the Presentation include, but
are not limited to, MindMed's ability to raise capital to complete
its plans and fund its studies, the medical and commercial
viability of the contemplated medicines and treatments being
developed, and the ability of MindMed to raise additional capital
in the future as MindMed continues to develop its products.
Although the Company believes that the expectations reflected in
such forward-looking information are reasonable, such information
involves risks and uncertainties, and undue reliance should not be
placed on such information, as unknown or unpredictable factors
could have material adverse effects on future results, performance
or achievements of the Company. There are numerous risks and
uncertainties that could cause actual results and the Company's
plans and objectives to differ materially from those expressed in
the forward-looking information, including compliance with laws and
regulations; difficulty associated with research and development;
risks associated with clinical trials or studies; heightened
regulatory scrutiny; early stage product development; clinical
trial risks; regulatory approval processes; novelty of the
psychedelic inspired medicines industry; as well as those risk
factors discussed or referred to herein and the risks described
under the headings "Risk Factors" in the Company's filings with the
securities regulatory authorities in all provinces and territories
of Canada which are available
under the Company's profile on SEDAR at www.sedar.com and with the
U.S. Securities and Exchange Commission on EDGAR at www.sec.gov.
Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking information prove
incorrect, actual results and future events could differ materially
from those anticipated in such information. Although the Company
has attempted to identify important risks, uncertainties and
factors that could cause actual results to differ materially, there
may be others that cause results not to be as anticipated,
estimated or intended. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend and does not assume any obligation to
update this forward-looking information.
Media Contact: mindmed@150bond.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mindmed-announces-shareholder-meeting-results-301301336.html
SOURCE Mind Medicine (MindMed) Inc.